IN2012DN03187A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03187A IN2012DN03187A IN3187DEN2012A IN2012DN03187A IN 2012DN03187 A IN2012DN03187 A IN 2012DN03187A IN 3187DEN2012 A IN3187DEN2012 A IN 3187DEN2012A IN 2012DN03187 A IN2012DN03187 A IN 2012DN03187A
- Authority
- IN
- India
- Prior art keywords
- present
- glp
- treat
- muscle atrophy
- prevent muscle
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 3
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 2
- 206010028289 Muscle atrophy Diseases 0.000 abstract 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 2
- 230000020763 muscle atrophy Effects 0.000 abstract 2
- 201000000585 muscular atrophy Diseases 0.000 abstract 2
- 230000035764 nutrition Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172398A EP2311486A1 (en) | 2009-10-07 | 2009-10-07 | GLP-2 for use in intestine and muscle recovery |
| PCT/EP2010/065021 WO2011042501A2 (en) | 2009-10-07 | 2010-10-07 | The intestine and muscle recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03187A true IN2012DN03187A (es) | 2015-09-25 |
Family
ID=41611235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3187DEN2012 IN2012DN03187A (es) | 2009-10-07 | 2010-10-07 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120270786A1 (es) |
| EP (2) | EP2311486A1 (es) |
| JP (1) | JP5801814B2 (es) |
| CN (1) | CN102711803B (es) |
| AU (1) | AU2010305420B2 (es) |
| BR (1) | BR112012009380A2 (es) |
| CA (1) | CA2776964C (es) |
| DK (1) | DK2485756T3 (es) |
| ES (1) | ES2539917T3 (es) |
| HK (1) | HK1173949A1 (es) |
| IN (1) | IN2012DN03187A (es) |
| WO (1) | WO2011042501A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015025490B1 (pt) * | 2013-04-15 | 2022-05-03 | Société des Produits Nestlé S.A. | Uso de uma fonte de aminoácidos em combinação com o estímulo muscular elétrico |
| JP6325215B2 (ja) * | 2013-08-29 | 2018-05-16 | テルモ株式会社 | 栄養補給用冷菓 |
| ES2960218T3 (es) * | 2014-10-14 | 2024-03-01 | Nestle Sa | Mejora en la funcionalidad del músculo de hombres ancianos |
| KR101661332B1 (ko) | 2015-05-28 | 2016-09-29 | (의료)길의료재단 | 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물 |
| US10993993B2 (en) | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
| KR102119188B1 (ko) * | 2018-11-13 | 2020-06-08 | 이뮤노포지 주식회사 | 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5661123A (en) * | 1995-01-17 | 1997-08-26 | Nestec, Ltd. | Enteral composition for malabsorbing patients |
| US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5834428A (en) * | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6852690B1 (en) * | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| ATE227309T1 (de) * | 1996-04-12 | 2002-11-15 | Ontario Inc 1149336 | Analoge des glucagon ähnlichen peptides -2 |
| CA2223198A1 (en) * | 1997-01-14 | 1998-07-14 | Societe Des Produits Nestle S.A. | Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
| CA2236519C (en) * | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| EP1090636A1 (en) * | 1999-09-13 | 2001-04-11 | Société des Produits Nestlé S.A. | High lipid diet |
| US7186683B2 (en) * | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| ATE396738T1 (de) * | 2000-09-18 | 2008-06-15 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
| JP4280070B2 (ja) * | 2001-02-16 | 2009-06-17 | コンジュケム バイオテクノロジーズ インコーポレイテッド | 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２） |
| KR20050059258A (ko) * | 2002-10-14 | 2005-06-17 | 노보 노르디스크 에이/에스 | Ｇｌｐ-2 화합물, 제제, 및 그것의 사용 |
| US20040115708A1 (en) * | 2002-10-28 | 2004-06-17 | Ardies C. Murray | Method of screening agents for the treatment and prevention of cancer and cachexia and the new use of specific agents for the treatment and prevention of cancer and cachexia |
| ATE549028T1 (de) * | 2003-05-15 | 2012-03-15 | Tufts College | Stabile analoga von glp-1 |
| RU2421076C2 (ru) * | 2005-04-06 | 2011-06-20 | Нестек С.А. | Способ и композиция для улучшения с помощью питания регуляции глюкозы и действия инсулина |
| CN101365350A (zh) * | 2006-01-09 | 2009-02-11 | 雀巢技术公司 | 应激患者的治疗 |
| CN101573376B (zh) * | 2006-11-08 | 2013-11-06 | 西兰制药公司 | 选择性胰高血糖素样肽-2（glp-2）类似物 |
-
2009
- 2009-10-07 EP EP09172398A patent/EP2311486A1/en not_active Withdrawn
-
2010
- 2010-10-07 WO PCT/EP2010/065021 patent/WO2011042501A2/en active Application Filing
- 2010-10-07 JP JP2012532595A patent/JP5801814B2/ja active Active
- 2010-10-07 BR BR112012009380-0A patent/BR112012009380A2/pt not_active Application Discontinuation
- 2010-10-07 EP EP10762684.8A patent/EP2485756B1/en active Active
- 2010-10-07 DK DK10762684.8T patent/DK2485756T3/en active
- 2010-10-07 US US13/500,784 patent/US20120270786A1/en not_active Abandoned
- 2010-10-07 AU AU2010305420A patent/AU2010305420B2/en active Active
- 2010-10-07 IN IN3187DEN2012 patent/IN2012DN03187A/en unknown
- 2010-10-07 ES ES10762684.8T patent/ES2539917T3/es active Active
- 2010-10-07 CN CN201080055259.6A patent/CN102711803B/zh active Active
- 2010-10-07 CA CA2776964A patent/CA2776964C/en active Active
-
2013
- 2013-01-22 HK HK13100959.4A patent/HK1173949A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010305420B2 (en) | 2015-03-19 |
| EP2485756A2 (en) | 2012-08-15 |
| WO2011042501A3 (en) | 2011-06-03 |
| JP2013507341A (ja) | 2013-03-04 |
| BR112012009380A2 (pt) | 2021-06-22 |
| WO2011042501A2 (en) | 2011-04-14 |
| ES2539917T3 (es) | 2015-07-07 |
| DK2485756T3 (en) | 2015-06-08 |
| CN102711803A (zh) | 2012-10-03 |
| CN102711803B (zh) | 2017-02-22 |
| CA2776964A1 (en) | 2011-04-14 |
| EP2485756B1 (en) | 2015-05-20 |
| JP5801814B2 (ja) | 2015-10-28 |
| CA2776964C (en) | 2019-03-05 |
| AU2010305420A1 (en) | 2012-05-10 |
| EP2311486A1 (en) | 2011-04-20 |
| US20120270786A1 (en) | 2012-10-25 |
| HK1173949A1 (en) | 2013-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN01638A (es) | ||
| MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| IL210810A0 (en) | Compositions for the treatment of pain and/or inflamtion | |
| JO2975B1 (en) | Formulation to improve sexual health | |
| IL268519A (en) | Useful preparations in the treatment of spinal muscular atrophy | |
| MX2011007930A (es) | Conjugados de insulina cristalina. | |
| MY153948A (en) | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | |
| EP2384198A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL INJURIES | |
| MX337575B (es) | Compuestos de sulfona y métodos para lafabricación y uso de éstos. | |
| IL184312A0 (en) | Herbal compositions for the treatment of diabetes and/or conditions associated therewith | |
| IN2012DN00624A (es) | ||
| MX345535B (es) | Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso. | |
| IN2012DN02624A (es) | ||
| IN2012DN03187A (es) | ||
| HK1173379A1 (en) | Compositions comprising tramadol and celecoxib in the treatment of pain | |
| ZA201109086B (en) | Prevention and treatment of allergic diarrhoea | |
| MX369699B (es) | Ácido graso del aceite de bogol para uso en suplementos y composiciones de tratamiento y piensos para animales. | |
| WO2011044523A3 (en) | Compositions and methods for treating obesity | |
| MX2011011860A (es) | Composicion estimulante inmune que comprende un extracto de aronia sp. en combinacion con selenio y/o zinc. | |
| MX2016005092A (es) | Composiciones farmaceuticas de estradiol insertadas en la vagina y metodos. | |
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
| EP2597949A4 (en) | SUBMIKROMETERZUSAMMENSETZUNGEN | |
| PL2375912T3 (pl) | Kompozycje i sposoby leczenia uczucia dyskomfortu gardła | |
| MX2018007398A (es) | Composicion para mejorar la sensacion bucal. |